Ai-driven development of a natural sweetener protein in camelina seed
Alkion BioInnovations is developing a novel, high-intensity sweetener protein in Camelina Sativa seeds using AI-driven protein design and CRISPR-Cas9 technology, targeting 2-8% of total soluble proteins. The project aims to create a natural, economically viable sweetener.
Overview
Alkion BioInnovations is pioneering the development of a novel, natural high-intensity sweetener derived from Camelina Sativa seeds. Utilizing AI-driven protein design tools, the research focuses on modifying a major protein in the seed to exhibit sweetening properties akin to natural sweet proteins. The goal is to achieve a protein that constitutes 2-8% of the total soluble proteins in Camelina, offering a potentially economically viable alternative to traditional sweeteners.
Technical specifications
The project employs sophisticated AI tools such as AlphaFold and proprietary software to predict the minimal protein transformations needed. The research leverages CRISPR-Cas9 technology to edit the genes of Camelina Sativa, aiming for precise modifications that impart sweetness to the protein. Key steps include optimizing plasmids for plant transformation, conducting initial tests in tobacco leaves, and validating the sweetness of the proteins through various iterations of gene editing.
Technology readiness level
Currently at Technology Readiness Level 3, this project is in the early stages of development. Preliminary experiments have shown feasibility in imparting sweetness to Camelina proteins, and further validation steps are planned to optimize and confirm the effectiveness of the transformation process. The team is focused on advancing through design and validation phases to bring this innovative sweetener closer to market readiness.
About Alkion BioInnovations
Alkion BioInnovations is a biotechnology company that has developed a proprietary plant tissue propagation and bioproduction platform. The company utilizes innovative hydroponic methods and specialized bioreactors to stimulate plant genes, enabling the production of high-value active compounds with high yields, purity, and batch-to-batch consistency. By employing a carbon-neutral approach in confined bioreactors, their technology provides an alternative to traditional, often unsustainable, extraction methods. The platform is designed to produce a variety of molecules, including vaccine adjuvants like QS-21, recombinant proteins, and natural sweeteners, while significantly reducing production costs, energy usage, and environmental impact compared to conventional greenhouse cultivation.
These solutions are critical for partners and customers in the pharmaceutical, nutraceutical, and agrifood industries who require scalable, sustainable, and secure supply chains for rare or difficult-to-source natural ingredients. By enabling large-scale, year-round production of potent molecules in a controlled environment, Alkion helps address supply chain constraints for essential medical treatments and food ingredients. The company has gained industry recognition, including support from the European Innovation Council Accelerator and various research grants, and works with global health organizations and industrial partners to improve the accessibility and affordability of breakthrough active compounds.
delivered to your inbox.